Glioblastoma is a formidable brain tumor known for its quick growth and unresponsiveness to typical treatments. Studies are constantly underway to identify new management strategies, and recently, a novel biomarker named LCA168 has emerged as a potential target for GBM treatment. LCA168 is a protei